Adelaide, Australia, 29 April 2022: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence, is pleased to release its Appendix 4C – Quarterly Cashflow report and business update for the quarter ended 31 March 2022 (the Quarter). All financial results are in Australian dollars and are unaudited.
Key Highlights
* First Thermo Fisher purchase orders received for five APAS® instruments
* APAS® Independence showcased at leading microbiology conferences
* Five clinical studies featuring the APAS® Independence presented at ECCMID
* Integration of Clever Culture Systems Joint Venture completed
* R&D Tax Incentive of $824,500 received
* 31 March 2022 cash balance of $5.6 million
For more information, download the attached PDF.
Download this document
